Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).


7565 Background: Sorafenib (S) is an oral multikinase inhibtor. The safety, antitumor activity, and pharmacokinetics of the combination of S with B/P/C were evaluated in chemonaive patients (pts) with advanced NSCLC. METHODS Pts (>18 yo) with Stage IIIB/IV non-squamous NSCLC and ECOG PS 0-1 were eligible for enrollment in this multicenter, phase I trial… (More)


  • Presentations referencing similar topics